Key points are not available for this paper at this time.
Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Leah H. Biller
Deborah Schrag
JAMA
Harvard University
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...
Biller et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d77e9af44a16d01ef31648 — DOI: https://doi.org/10.1001/jama.2021.0106